Abstract: Multiple system atrophy (MSA) is a neurodegenerative disease not only affecting the basal ganglia, brainstem, cerebellum, and intermediolateral cell columns of the spinal cord but also the cerebral cortex.
tion in MSA along the middle cerebellar peduncles, reflecting degeneration of the ponto-cerebellar tract as a particularly prominent and progressive morphological alteration in MSA. Comparisons between baseline and follow-up, separately performed in patients and controls, revealed additional white matter reduction in MSA along the corpus callosum at follow-up. This was replicated through additional shape-based analyses indicating a reduced callosal thickness in the anterior and posterior midbody, extending posteriorly into the isthmus. Callosal atrophy may possibly reflect a disease-specific pattern of neurodegeneration and cortical atrophy, fitting well with the predominant impairment of motor functions in the MSA patients.
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Key words: MSA; MSA-C; MSA-P; VBM; corpus callosum; follow-up Multiple system atrophy (MSA) is a sporadic, adultonset disease characterized by progressive neurodegeneration in various parts of the central nervous system involving not only the basal ganglia, brainstem, cerebellum, and intermediolateral cell columns of the spinal cord but also the cerebral cortex.
1,2 Neuropathological hallmark of MSA are a-synuclein-positive oligodendroglial cytoplasmic inclusions (GCIs). 3 Clinically, MSA patients present with various combinations of parkinsonism, cerebellar ataxia, and autonomic failure, most notably orthostatic hypotension and urinary incontinence. According to the clinical presentation, a parkinsonian (MSA-P) and a cerebellar variant of MSA (MSA-C) are distinguished. 4, 5 MSA shows a rapid clinical progression; many patients are wheel-chair-bound after 5 years of disease duration and often die only a few years later. [5] [6] [7] Currently, neither protective nor curative treatments are available. Future clinical trials may test the efficacy of treatments that aim to reduce the rate of progression of this fatal disease. Thus, biomarkers to reliably quantify disease progression during lifetime are essential.
Magnetic resonance imaging (MRI) has been extensively used to study brain morphology in MSA patients. Different MRI analysis techniques, such as regions of interest (ROI)-based analysis of T1-weighted and diffusion-weighted images (DWI), voxel-based morphometry (VBM), voxel-based relaxometry, diffusion tensor imaging (DTI), or magnetization transfer imaging are useful for detecting disease-related morphological changes in the cerebellum, middle cerebellar peduncles, brainstem, striatum, corpus callosum, and cortical regions in vivo. [7] [8] [9] [10] [11] [12] [13] The progression of atrophy over time has been studied only recently using different MRI methods detecting regionally varying annual rates of atrophy or signal alterations, partly correlating with clinical progression, and evidence of widespread subcortical gray matter loss during follow-up. Those studies have focused on predefined regions or were restricted to analyzing gray matter changes and most of them applied only one morphometric method. 9, 11, [14] [15] [16] However, applying diverse morphometric methods within one study can be advantageous, because it allows a direct comparison of methods, thus improving the validity of the results.
The aim of this study was to investigate the progression of both gray and white matter reduction during a 1-year follow-up period in 14 MSA patients of both clinical subtypes, to identify structural parameters that might be useful for measuring disease progression. For this purpose, we combined the application of two different methods, VBM and a computational surfacebased morphometric method to specifically evaluate the thickness of the corpus callosum.
PATIENTS AND METHODS

Subjects
The study was performed in 14 MSA patients (10 MSA-C, 4 MSA-P, men: 7, women: 7; age: 61.1 6 3.3 years; disease duration: 3.4 6 1.6 years) and 14 healthy controls without history of neurological or psychiatric disorder and with a normal neurological examination (men: 7, women: 7; age 58.6 6 5.1 years). Diagnosis of MSA was made according to the established criteria. 17 Patients and healthy controls underwent MRI imaging and neurological examination twice in a time interval of 1 year [time span in between: 14.6 6 3.0 years (MSA group) and 16.7 6 6.1 (control group)].
The study was approved by the ethics committee of the Medical Faculty of the University of Bonn. Informed, written consent was obtained from all participants.
Data Acquisition
MRI was performed using a 1.5-T scanner (Siemens Symphony, Siemens AG, Erlangen, Germany) with the standard head coil. The MRI protocol comprised a sagittal T1-weighted (MPRAGE) sequence (repitition time (TR) 11.08 ms, echo time (TE) 4.3 ms, flipping angle (FA) 158, field of view (FOV) 230 mm, 256 3 256 acquisition matrix) yielding 200 sagittal slices and a voxel size of 0.9 3 0.9 3 0.9 mm 3 .
Voxel-Based Morphometry
The data were processed according to our previously described protocol 13 using statistical parametric mapping (SPM), only differing by the use of the updated version SPM5 instead of SPM2 (SPM5, http://www.fil.ion.ucl.ac. uk/spm/software/spm5). This protocol comprises a series of preprocessing steps, which were verified separately for each subject. As a first step, the anterior commissure was set in each image as the origin of the individual stereotaxic space. Further processing was performed according to the protocol originally described by Good et al. 18 and adapted for the use with SPM5. This revised procedure optimizes the normalization and segmentation for the tissue type examined, using a unified segmentation method. 19 In short, tissue probability maps, provided by the SPM5 software, are overlaid by nonlinear deformations onto the individual anatomy and used as priors to segment the original image into the three tissue classes, gray matter, white matter, and cerebro-spinal fluid. The procedure also includes a bias correction of the data to compensate for inhomogeneities in the distribution of voxel intensities across each tissue class. The resulting normalized and segmented images were resampled to a voxel size of 1.5 3 1.5 3 1.5 mm 3 and smoothed with a 12-mm Gaussian kernel.
Using the smoothed tissue segments, the following statistical comparisons were performed, separately, for gray and white matter: (1) two-sample t-tests between MSA patients and controls at baseline and at follow-up; (2) paired t-tests comparing MRI images at baseline and at follow-up, separately for MSA patients and controls; and (3) two-sample t-tests of difference maps comparing MSA patients and controls, where individual difference maps were created by subtracting gray and white matter maps at follow-up from baseline (map baseline 2 map follow-up ). The results were explored at a false discovery rate (FDR)-corrected threshold of P < 0.05 as voxelwise threshold and a family wise error (FWE)-corrected threshold of P < 0.05 for the extent of the respective cluster. All statistical comparisons were controlled for global differences by including the overall brain volume as a confounding covariate in the design matrix.
Callosal Thickness Analysis
The corpus callosum was outlined in normalized data after applying six-parameter (rigid body) transformations. An overview of the basic steps for measuring callosal thickness is provided elsewhere. 20 Briefly, one rater (E.L.) manually outlined upper and lower callosal boundaries in the midsagittal section of each brain. Sub- sequently, the spatial average from 100 equidistant surface points representing the upper and lower traces was calculated by creating a new midline segment, also consisting of 100 equidistant points. Finally, distances between the midline segment and the 100 corresponding surface points of the upper and lower callosal segments were quantified. These regional distances indicate callosal thickness with a high spatial resolution (i.e., at 100 locations distributed evenly over the callosal surface). Using the callosal distance values, the following statistical comparisons were performed: (1) two-sample t-tests between MSA patients and controls at baseline and at follow-up; and (2) paired t-tests comparing MRI images at baseline and at follow-up, separately for MSA patients and controls. As statistical tests were made at hundreds of callosal surface points and adjacent data points are highly correlated, statistical results were corrected for multiple comparisons using the FDR method at P < 0.05. 21 Both uncorrected and corrected maps were generated and displayed.
RESULTS
Gray Matter
Group comparison at baseline revealed that MSA patients had less gray matter than controls in cerebellar hemispheres, left cingulum and in several cortical regions, including bifrontal and left insular regions. At follow-up, we found a more pronounced reduction of gray matter in MSA patients in initially affected regions and additional gray matter reduction in thalamic and caudate nuclei.
Comparison of the follow-up and baseline images with paired t-tests detected gray matter reduction in initially affected brain regions and additionally in the right and left caudate nucleus, right thalamus, and right cingulum. In contrast, two-sample t-tests of difference maps comparing MSA and control group did not depict any gray matter reduction during the follow-up period (Table 1) .
White Matter
Group comparisons at baseline revealed that MSA patients had less white matter than controls along the middle cerebellar peduncles and brainstem (corticospinal tract) bilaterally. At follow-up, we found more pronounced reduction in previously affected regions and additional white matter reduction along the corticospinal tract bilaterally.
Comparison of the follow-up and baseline images with paired t-tests revealed white matter reduction in initially affected brain regions and additionally along the corticospinal tracts (left and right internal capsule, subcortical to left precentral gyrus) and along the entire corpus callosum. The two-sample t-tests comparing difference maps between MSA patients and controls similarly showed white matter reduction during the follow-up period in cerebellum, middle cerebellar peduncles, and subcortical to left precentral gyrus, but did not depict changes of corticospinal tracts at further levels or the corpus callosum (Table 2) .
Callosal Thickness
As shown in Figure 1 (top panels), callosal regions were thinner in MSA patients when compared with healthy controls. The difference was more pronounced at follow-up (panel B) than at baseline (panel A). At baseline, the corpora callosa of MSA patients were thinner mainly across the anterior and posterior body. At followup, the isthmus was additionally affected. We did not detect any region in which callosal thickness was thicker in MSA patients when compared with controls.
Furthermore, as shown in Figure 1 (bottom panels), callosal thickness declined over time. The decline was more pronounced in MSA patients (panel C) than in controls (panel D). More specifically, the thickness of the corpora callosa in MSA patients mainly decreased in the isthmus. The thickness of the corpora callosa of controls slightly declined in the splenium and in the anterior third, but this decline did not reach the level of statistical significance. We did not detect any region, in MSA patients or in controls, in which callosal thickness increased over time.
DISCUSSION
We performed a 1-year longitudinal MRI study of 14 MSA patients to investigate the progression of brain tissue loss in MSA. Comparison of MSA patients with controls confirmed a reduction of gray matter in the cerebellum and certain cortical areas and a reduction of white matter in the cerebellum, cerebellar peduncles, and brainstem, already detectable at baseline. Analysis of the follow-up MRIs revealed further progression of brain matter loss.
The MSA within-group comparison between baseline and follow-up as well as the comparison of MSA patients and controls at follow-up showed progressive gray and white matter reduction mainly in regions that were already affected at baseline. Interestingly, these areas partly show resemblance with areas normally affected by age-related shrinkage (i.e., in healthy subjects). For example, the progressive reduction of the brainstem and cerebellum is well documented to occur during normal aging and is most prominent after the age of 50 years. 22, 23 This might also explain why the comparison of difference maps between MSA and controls did not reveal progressive tissue loss in all those regions, but only confirmed progressive white matter reduction of the middle cerebellar peduncles. As the latter approach (comparison of the difference maps) takes into account normal age-related decline of the brain, it may be more appropriate to depict diseasespecific changes.
White matter tissue reduction along the middle cerebellar peduncles likely reflects a degeneration of the pontocerebellar tract as a particularly prominent and progressive morphological alteration in MSA brains. This finding is in-line with the results of recent morphometric studies investigating tissue-specific properties such as diffusivity (DWI, DTI) instead of MRI-signal alterations (VBM). These studies similarly identified degeneration of the middle cerebellar peduncles as a MSA-specific feature.
12,24-28 Therefore, atrophy of the middle cerebellar peduncles seems to be the most robust, aging-independent, and disease-specific atrophy in MSA.
MSA within-group comparison between baseline and follow-up revealed not only reduction of white matter in typically affected regions like middle cerebellar peduncles and corticospinal tract but also across the entire corpus callosum. VBM-primarily developed to study gray matter-generates smoothed probability maps of white matter for the final statistical comparison. Because of the methodological constraints, anatomical information contained within those maps may only have a limited precision regarding the exact anatomical localization of affected callosal subregions. The prominent involvement of the corpus callosum was therefore independently validated by a second morphometric method to explore the regional pattern of callosal atrophy in MSA patients, in great detail. For this purpose, we investigated corpus callosum thickness at 100 points across the callosal surface. At baseline, we found a deficit in callosal thickness in MSA patients compared with controls in the anterior and posterior body, extending even further posteriorly at follow-up. According to a recent DTI-based study of callosal connectivity, the anterior midbody connects cortical premotor and supplementary motor regions between both hemispheres. 29 The posterior mid-body contains the highest density of fibers with a large diameter 30 and is linked to the primary motor cortex. 29 Thus, the observed pattern of callosal atrophy agrees closely with the predominant impairment of motor functions in MSA patients. As we investigated a mixed patient sample including MSA-C and MSA-P patients, further studies will need to determine whether callosal atrophy is equally associated with both clinical subtypes. So far, little attention has been paid to callosal atrophy in MSA, although GCIs have been observed in the corpus callosum as well.
3, 31 Watanabe et al. 7 used a ROI-based MRI approach and detected callosal atrophy in a subgroup of MSA patients, not correlating with disease duration. Because they also found signs of cortical atrophy in MSA patients with callosal atrophy, the authors suggested a link between cortical and callosal atrophy. Another study found callosal atrophy only in MSA-P but not in MSA-C patients. 32 Cerebellar atrophy, especially of the middle cerebellar peduncles, is one of the most prominent findings in MSA, but its degree depends on the clinical subtype and is highly variable, whereas the degree of cortical atrophy was more similar in both subtypes. 10, 33, 34 To validate new therapies it would be advantageous to have morphological markers of disease progression independently of the clinically dominant symptom. If callosal atrophy occurs as a result of Wallerian degeneration, it can serve as an indirect neuroanatomical marker for cortical atrophy. Especially, neuronal loss in the third cortical layer results in axonal degeneration and consecutive callosal atrophy and has been described in neurodegenerative disorders like Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, and corticobasal degeneration. [35] [36] [37] Separation of age-related from disease-related callosal atrophy is critical and essential for its use as morphological marker in follow-up investigations. However, regionally circumscribed callosal atrophy as described here for MSA may possibly reflect a disease-specific pattern of neurodegeneration and cortical atrophy.
